Summary:- INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
Tag:
Sanofi
-
-
RegulatoryU.S FDA
The FDA has Approved TZIELDTM (Teplizumab-mzwv) as the First and Only Medication Intended to Postpone the onset of Stage 3 Type 1 Diabetes (T1D) in Adult and Paediatric Patients with Stage 2 T1D Who are 8 Years of Age and Older.
by adminby adminSummary:- TZIELD is the first disease-modifying therapy in T1D, a life-threatening autoimmune disease In a clinical trial, in Stage 2 T1D patients,…
-
RegulatorySanofi Inc.U.S FDA
XenpozymeTM (Olipudase alfa-rpcp) Approved by FDA as First Disease-Specific Treatment for Acid Sphingomyelinase Deficiency, a Rare Genetic Disease to Sanofi
by adminby adminSummary: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations) Xenpozyme is the first approved medication to treat symptoms that are not related…
-
Pharma Science & ResearchSanofi
Sanofi and Innovent Biologics Enter Strategic Collaboration
by adminby adminSanofi and Innovent Biologics have announced a collaboration that will bring innovative medicines to patients in China with difficult-to-treat cancers. Innovent is…
-
IndiaPatent Litigation
Panacea Biotec Files Suit against Sanofi for Patent Infringement for EasySix Vaccine
by adminby adminSummary : Panacea Biotec on Monday said it has filed a suit before the Delhi High Court seeking to restrain Sanofi Healthcare…
-
Global MarketRegulatorySanofi Inc.U.S FDA
FDA Approves Dupixent®(Dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
by adminby adminSummary : Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced…
-
Pharma Science & ResearchSanofi Inc.
Nirsevimab first potential immunisation to protect against RSV in infants
by adminby adminSynopsis : Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in…
-
RegulatorySanofi Inc.U.S FDA
Nexviazyme® improves respiration and mobility long-term in Pompe disease patients
by adminby adminSummary : Two-year data shows Pompe disease patients treated with Nexviazyme® (avalglucosidase alfa) have sustained improvements in respiratory function and mobility. Sanofi has…
-
Covid DrugsGskSanofi Inc.
Data delivery: Sanofi and GSK seek authorisation for COVID-19 vaccine
by adminby adminSynopsis : Pharma giants take major stride as vaccine shows significant increase in neutralising antibodies Sanofi and GlaxoSmithKline (GSK) have announced that…
-
Summary : Sanofi announced the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine…
Newer Posts